Tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ponesimod in male and female volunteers

Trial Profile

Tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ponesimod in male and female volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2014

At a glance

  • Drugs Ponesimod (Primary)
  • Indications Graft-versus-host disease; Immunological disorders; Multiple sclerosis; Plaque psoriasis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 20 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top